

## **METHENAMINE HIPPURATE- methenamine hippurate tablet**

### **Viona Pharmaceuticals Inc**

-----

#### **Methenamine Hippurate Tablets, USP**

To reduce the development of drug-resistant bacteria and maintain the effectiveness of methenamine hippurate tablets and other antibacterial drugs, methenamine hippurate tablets should be used only to treat or prevent infections that are proven or strongly suspected to be caused by bacteria.

#### **DESCRIPTION**

Each white to off-white colored, modified capsule-shaped tablet contains 1 g methenamine hippurate, USP which is the hippuric acid salt of methenamine (hexamethylene tetramine). In addition, each tablet contains the following inactive ingredients: crospovidone, colloidal silicon dioxide, magnesium stearate, povidone and saccharin sodium.

FDA approved dissolution test specifications differ from USP.

#### **ACTIONS**

##### **Microbiology**

Methenamine hippurate tablets has antibacterial activity because the methenamine component is hydrolyzed to formaldehyde in acid urine. Hippuric acid, the other component, has some antibacterial activity and also acts to keep the urine acid. The drug is generally active against *E. coli*, enterococci and staphylococci. *Enterobacter aerogenes* is generally resistant. The urine must be kept sufficiently acid for urea-splitting organisms such as *Proteus* and *Pseudomonas* to be inhibited.

##### **Human Pharmacology**

Within 1/2 hour after ingestion of a single 1 gram dose of methenamine hippurate, antibacterial activity is demonstrable in the urine. Urine has continuous antibacterial activity when methenamine hippurate is administered at the recommended dosage schedule of 1 gram twice daily. Over 90% of methenamine moiety is excreted in the urine within 24 hours after administration of a single 1 gram dose. Similarly, the hippurate moiety is rapidly absorbed and excreted, and it reaches the urine by both tubular secretion and glomerular filtration. This action may be important in older patients or in those with some degree of renal impairment.

#### **INDICATIONS**

Methenamine hippurate tablets are indicated for prophylactic or suppressive treatment of frequently recurring urinary tract infections when long-term therapy is considered necessary. This drug should only be used after eradication of the infection by other appropriate antimicrobial agents.

To reduce the development of drug-resistant bacteria and maintain the effectiveness of methenamine hippurate tablets and other antibacterial drugs, methenamine hippurate tablets should be used only to treat or prevent infections that are proven or strongly suspected to be caused by susceptible bacteria. When culture and susceptibility information are available, they should be considered in selecting or modifying antibacterial therapy. In the absence of such data, local epidemiology and susceptibility patterns may contribute to the empiric selection of therapy.

## CONTRAINDICATIONS

Methenamine hippurate tablets are contraindicated in patients with renal insufficiency, severe hepatic insufficiency, or severe dehydration. Methenamine preparations should not be given to patients taking sulfonamides because some sulfonamides may form an insoluble precipitate with formaldehyde in the urine.

## WARNING

Large doses of methenamine (8 grams daily for 3 weeks to 4 weeks) have caused bladder irritation, painful and frequent micturition, albuminuria, and gross hematuria.

## PRECAUTIONS

Prescribing methenamine hippurate in the absence of a proven or strongly suspected bacterial infection or a prophylactic indication is unlikely to provide benefit to the patient and increases the risk of the development of drug-resistant bacteria.

1. Care should be taken to maintain an acid pH of the urine, especially when treating infections due to urea-splitting organisms such as *Proteus* and strains of *Pseudomonas*.
2. In a few instances in one study, the serum transaminase levels were slightly elevated during treatment but returned to normal while the patients were still taking methenamine hippurate. Because of this report, it is recommended that liver function studies be performed periodically on patients taking the drug, especially those with liver dysfunction.
3. Use in Pregnancy: In early pregnancy the safe use of methenamine hippurate is not established. In the last trimester, safety is suggested, but not definitely proved. No adverse effects on the fetus were seen in studies in pregnant rats and rabbits. Methenamine hippurate taken during pregnancy can interfere with laboratory tests of urine estriol (resulting in unmeasurably low values) when acid hydrolysis is used in the laboratory procedure. This interference is due to the presence in the urine of methenamine and/or formaldehyde. Enzymatic hydrolysis, in place of acid hydrolysis, will circumvent this problem.

## Geriatric Use

Clinical studies of methenamine hippurate did not include sufficient numbers of subjects aged 65 and over to determine whether they respond differently from younger subjects. Other reported clinical experience has not identified differences in responses between the elderly and younger patients. In general, dose selection for an elderly patient should be cautious, usually starting at the low end of the dosing range, reflecting the greater

frequency of decreased hepatic, renal or cardiac function, and of concomitant disease or other drug therapy.

Methenamine hippurate tablets are contraindicated in patients with renal insufficiency and severe hepatic insufficiency (see **CONTRAINDICATIONS**).

### ***Information for Patients***

Patients should be counseled that antibacterial drugs including methenamine hippurate should only be used to treat bacterial infections. They do not treat viral infections (e.g., the common cold). When methenamine hippurate tablets are prescribed to treat a bacterial infection, patients should be told that although it is common to feel better early in the course of therapy, the medication should be taken exactly as directed. Skipping doses or not completing the full course of therapy may (1) decrease the effectiveness of the immediate treatment and (2) increase the likelihood that bacteria will develop resistance and will not be treatable by methenamine hippurate or other antibacterial drugs in the future.

### **ADVERSE REACTIONS**

Minor adverse reactions have been reported in less than 3.5% of patients treated. These reactions have included nausea, upset stomach, dysuria, and rash.

**To report SUSPECTED ADVERSE REACTIONS, contact Viona Pharmaceuticals Inc. at 1-888-304-5011 or FDA at 1-800-FDA-1088 or [www.fda.gov/medwatch](http://www.fda.gov/medwatch).**

### **DOSAGE AND ADMINISTRATION**

1 tablet (1 g) twice daily (morning and night) for adults and pediatric patients over 12 years of age. 1/2 to 1 tablet (0.5 g to 1 g) twice daily (morning and night) for pediatric patients 6 years to 12 years of age. Since the antibacterial activity of methenamine hippurate tablets is greater in acid urine, restriction of alkalinizing foods and medications is desirable. If necessary, as indicated by urinary pH and clinical response, supplemental acidification of the urine should be instituted. The efficacy of therapy should be monitored by repeated urine cultures.

### **HOW SUPPLIED**

Methenamine hippurate tablets, USP are white to off-white colored, modified capsule-shaped, uncoated tablets, debossed with "II" and "C" on one side and score line on both the sides.

NDC 72578-175-01 in bottle of 100 tablets with child-resistant closure

Store at 20°C to 25°C (68°F to 77°F); excursions permitted between 15°C to 30°C (59°F to 86°F) [See USP Controlled Room Temperature].

Dispense in well-closed, light-resistant container with child-resistant closure.

**Manufactured by:**

**Zydus Pharmaceuticals Ltd.**

Ahmedabad-382213, India

**Distributed by:**

**Viona Pharmaceuticals Inc.**

Cranford, NJ 07016

Rev.: 05/24


**PACKAGE LABEL.PRINCIPAL DISPLAY PANEL**

NDC 72578-175-01

Methenamine Hippurate Tablets, USP 1gram

100 tablets

Rx only



**METHENAMINE HIPPURATE**

methenamine hippurate tablet

**Product Information**

<b>Product Type</b>	HUMAN PRESCRIPTION DRUG	<b>Item Code (Source)</b>	NDC:72578-175
<b>Route of Administration</b>	ORAL		

**Active Ingredient/Active Moiety**

Ingredient Name	Basis of Strength	Strength
METHENAMINE HIPPURATE (UNII: M329791L57) (METHENAMINE - UNII:J50OIX95QV)	METHENAMINE HIPPURATE	1 g

Inactive Ingredients

Ingredient Name	Strength
CROSPVIDONE, UNSPECIFIED (UNII: 2S7830E561)	
MAGNESIUM STEARATE (UNII: 70097M6I30)	
POVIDONE, UNSPECIFIED (UNII: FZ989GH94E)	
SACCHARIN SODIUM (UNII: SB8ZUX40TY)	
SILICON DIOXIDE (UNII: ETJ7Z6XBU4)	

Product Characteristics

Color	WHITE (WHITE TO OFF WHITE)	Score	2 pieces
Shape	CAPSULE (MODIFIED CAPSULE SHAPE)	Size	19mm
Flavor		Imprint Code	II;C
Contains			

Packaging

#	Item Code	Package Description	Marketing Start Date	Marketing End Date
1	NDC:72578-175-01	100 in 1 BOTTLE; Type 0: Not a Combination Product	03/12/2025	

Marketing Information

Marketing Category	Application Number or Monograph Citation	Marketing Start Date	Marketing End Date
ANDA	ANDA219661	03/12/2025	

Labeler - Viona Pharmaceuticals Inc (081468959)

Registrant - Zydus Lifesciences Limited (650199482)

Establishment

Name	Address	ID/FEI	Business Operations
Zydus Pharmaceuticals Limited		650173735	MANUFACTURE(72578-175) , ANALYSIS(72578-175)